Trade-Off for Better Balanced Nonlinear Optical Performance with Disordered Si in ZnGeP₂ by Shunda Yang (8086265)

“…Theoretical calculations with special quasirandom structures show that the NLO coefficient decreases gradually with increasing Si content, but the decrease is tiny in the 0–50% range and acute in the 50–100% range of Si. …”

Trade-Off for Better Balanced Nonlinear Optical Performance with Disordered Si in ZnGeP₂ by Shunda Yang (8086265)

“…Theoretical calculations with special quasirandom structures show that the NLO coefficient decreases gradually with increasing Si content, but the decrease is tiny in the 0–50% range and acute in the 50–100% range of Si. …”

Trade-Off for Better Balanced Nonlinear Optical Performance with Disordered Si in ZnGeP₂ by Shunda Yang (8086265)

“…Theoretical calculations with special quasirandom structures show that the NLO coefficient decreases gradually with increasing Si content, but the decrease is tiny in the 0–50% range and acute in the 50–100% range of Si. …”

Trade-Off for Better Balanced Nonlinear Optical Performance with Disordered Si in ZnGeP₂ by Shunda Yang (8086265)

“…Theoretical calculations with special quasirandom structures show that the NLO coefficient decreases gradually with increasing Si content, but the decrease is tiny in the 0–50% range and acute in the 50–100% range of Si. …”

Trade-Off for Better Balanced Nonlinear Optical Performance with Disordered Si in ZnGeP₂ by Shunda Yang (8086265)

“…Theoretical calculations with special quasirandom structures show that the NLO coefficient decreases gradually with increasing Si content, but the decrease is tiny in the 0–50% range and acute in the 50–100% range of Si. …”

Trade-Off for Better Balanced Nonlinear Optical Performance with Disordered Si in ZnGeP₂ by Shunda Yang (8086265)

“…Theoretical calculations with special quasirandom structures show that the NLO coefficient decreases gradually with increasing Si content, but the decrease is tiny in the 0–50% range and acute in the 50–100% range of Si. …”

Trade-Off for Better Balanced Nonlinear Optical Performance with Disordered Si in ZnGeP₂ by Shunda Yang (8086265)

“…Theoretical calculations with special quasirandom structures show that the NLO coefficient decreases gradually with increasing Si content, but the decrease is tiny in the 0–50% range and acute in the 50–100% range of Si. …”

Raw data. by Adrian Bartoszek (20826922)

“…Seizures were induced by adding PTZ to achieve a final concentration of 20 mM. In the PTZ-induced seizure model, the application of CAF in doses over 50 mg/L resulted in a decrease in the average movement. …”

Failure of Passive Immune Transfer in Calves: A Meta-Analysis on the Consequences and Assessment of the Economic Impact by Didier Raboisson (2833616)

“…As a result of the double-step stochastic method, the proposed economic estimation constitutes the first estimate available for FPT. …”

Effects of anaesthesia on a model for acoustic context effects on cortical neuron responses to natural sounds. by Luciana López-Jury (8601540)

“…(<b>A</b>) The decrease of the cortical input firing rate was implemented by systematically decreasing the average input rate parameter, ν, by a factor of 1.0 (awake model) to 0.5 in steps of 0.05. …”

Significantly Improved Water Oxidation of CoP Catalysts by Electrochemical Activation by Pengxia Ji (8163564)

“…Correspondingly, the voltage of the assembled CoP/CC||CoP/CC electrolyzer is also greatly decreased from 1.64 to 1.49 V at 10 mA cm^–2. …”

Data_Sheet_1_Elimination of hepatitis C in a hospital characterized by infectious diseases.PDF by Ying Han (137520)

“…The detection rate of HCV antibody among inpatients showed an upward trend (Z = 5.567, P < 0.001), while the positivity rate showed a downward trend (Z = 2.2926, P = 0.0219).</p>Conclusions<p>We found that even in hospitals characterized by infectious diseases, a large proportion of patients did not complete each step along a proposed HCV treatment cascade. …”

Temporal evolution of photophobic responses. by Kazunari Ozasa (1959577)

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”